Study guide

10.1 Immunotherapy

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

10.1 Immunotherapy

Key Takeaways Explain This Topic AI

PD-1/PD-L1 and CTLA-4 checkpoint inhibitors are less common first-line therapy in young children than in adults; they appear in relapsed, refractory, and selected solid-tumor or lymphoma settings, and inflammatory irAEs (colitis, pneumonitis, dermatitis) typically get high-dose corticosteroids first-line.

Dinutuximab (anti-GD2) causes expected neuropathic pain that is often managed with protocolized opioids plus gabapentinoids, plus capillary leak, hypotension, and electrolyte wasting.

Blinatumomab is a multi-day continuous infusion; cytokine release syndrome, neurotoxicity, bag integrity, and central-line security are the nursing product—never bolus to catch up.

Intrathecal immunotherapy must be preservative-free and IT-labeled, with the same route timeout as IT methotrexate and no vincristine on the field; systemic immunotherapy causes whole-body irAEs or CRS.

Premedications and bedside emergency drugs are required before the first drop; stop for anaphylaxis, refractory dinutuximab pain, capillary-leak crisis, or new blinatumomab neurologic change.

Last updated: August 2026

Immunotherapy uses the child's immune system—or laboratory-built antibodies that recruit it—to recognize cancer. CPHON Test Content Outline (TCO) III.A.3 and III.B.3 sit next to biotherapy on purpose. The last chapter taught rituximab, gemtuzumab, and tretinoin as biologics. This section is the immune-toxicity chapter: checkpoint-inhibitor immune-related adverse events (irAEs) , anti-GD2 dinutuximab as a full nursing protocol, blinatumomab as a multi-day living infusion, and the difference between systemic and intrathecal (IT) immunotherapy. Children's Oncology Group (COG) and Association of Pediatric Hematology/Oncology Nurses (APHON) practice, not a brand name, is what the Oncology Nursing Certification Corporation (ONCC) tests.

Checkpoint inhibitors: uncommon first-line in young children, still on the exam

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors (generic exemplars: pembrolizumab, nivolumab, atezolizumab) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitors (ipilimumab) take the brakes off T cells. In adults they are everyday first-line therapy for many solid tumors. In young children they are not typical first-line therapy for the common cooperative-group cancers (acute lymphoblastic leukemia, neuroblastoma, Wilms tumor, osteosarcoma). They appear in relapsed, refractory, and selected solid-tumor or lymphoma settings, on trials, and when a tumor has mismatch-repair deficiency or high mutational burden. Do not teach that every preschooler with a new diagnosis starts a PD-1 inhibitor on day 1. Do teach the toxicity pattern, because when a teenager with relapsed Hodgkin lymphoma or a child with a mismatch-repair–deficient tumor receives one, the nurse who thinks "this is just another antibody infusion reaction" will miss colitis, pneumonitis, and endocrine failure weeks later .

irAEs are the T-cell attack on self. Timing is delayed compared with a classic infusion reaction: dermatitis and colitis can appear during therapy or after the last dose. High-yield organs:

Colitis : frequent watery stools, cramping, nocturnal diarrhea, blood. This is not "chemo diarrhea" until proven otherwise. Hold the checkpoint inhibitor per protocol, notify, and start the workup for infection versus irAE. High-dose corticosteroids are the typical first-line treatment for moderate-to-severe inflammatory irAEs (colitis, pneumonitis, significant dermatitis) once infection is addressed per the team.

Pneumonitis : new cough, hypoxia, or infiltrates that are not routine infection. Hold the drug, give oxygen, image, and start steroids as ordered. A pulse-ox drop after pembrolizumab is not automatically "the winter virus."

Endocrinopathy : hypophysitis, thyroiditis (hyper then hypo), adrenal insufficiency, and hyperglycemia. Fatigue, headache, hypotension, and hyponatremia after a CTLA-4 or PD-1 inhibitor are endocrine emergencies until labs say otherwise. Established hypothyroidism needs hormone replacement (levothyroxine); adrenal crisis needs stress-dose hydrocortisone . Replacement can be lifelong even if the cancer is gone. Steroids treat hypophysitis and inflammatory crisis; they do not replace a missing hormone by themselves.

Dermatitis : rash and pruritus are common; blistering, mucosal involvement, or rapid progression is a stop-and-notify finding and a steroid-plus-dermatology problem.

The item that holds: inflammatory irAEs are treated with high-dose steroids first-line , not with "push through the infusion." Immunosuppression for irAEs then raises infection risk—teach families that steroids for colitis are treatment, not a contradiction of "boosting immunity." A 15-year-old on pembrolizumab who develops bloody diarrhea at home two weeks after a clinic dose needs same-day evaluation, not a message to wait for the next cycle.

Anti-GD2 dinutuximab: pain, leak, pressure, salt

Dinutuximab is a chimeric anti-GD2 monoclonal antibody used after consolidation in high-risk neuroblastoma . GD2 sits on neuroblastoma cells and on peripheral nerves, which is why the infusion hurts. Nursing is protocol, not optional comfort.

Neuropathic pain is expected. Many protocols protocolize opioids (often a hydromorphone or morphine infusion started before or with the antibody) plus a gabapentinoid (gabapentin or pregabalin) as co-analgesia. A 4-year-old who screams, arches, and says the legs are on fire is having GD2 neuropathy, not "acting out." Treat the pain. Rate holds and extra opioid boluses follow the protocol; do not withhold analgesia because pain "means it is working."

Capillary leak produces edema, rapid weight gain, pulmonary crackles, and hypoxia. Hypotension rides with leak and with the antibody itself. Have fluid-bolus orders, hold parameters, and a monitored setting that can escalate. Electrolyte wasting —hyponatremia, hypokalemia, and hypoalbuminemia-associated shifts—belongs on the chemistry panel, not only on the blood-pressure sheet. Weigh every shift. A 1-kg overnight gain in a 15-kg child is leak until proven otherwise.

Hypersensitivity (urticaria, bronchospasm, anaphylaxis) still occurs. Premeds commonly include an antihistamine, antipyretic, and sometimes a corticosteroid per protocol. First cycles run where you can escalate—not an unsupervised clinic chair.

Blinatumomab: the bag is the treatment

Blinatumomab is a CD19/CD3 bispecific T-cell engager used in B-ALL (measurable residual disease, relapsed/refractory disease, and selected front-line arms). It is not chimeric antigen receptor T-cell therapy and it is not a five-minute push. It is a continuous intravenous infusion lasting days, with scheduled bag changes . The pump, the tubing, and central-line security are the drug.

Prime and change bags on the pharmacy clock. An empty bag or an unrecognized disconnection is a missed dose and a clinical event.

Never bolus to "catch up" if the infusion ran behind. Restart at the ordered rate.

Line security : Luer-lock, lumen discipline so a toddler cannot tug the continuous bag off, no unapproved Y-site drugs, protection during showers and play. A disconnected blinatumomab line on the playroom floor is both a hazardous-drug problem and lost T-cell engagement.

Cytokine release syndrome (CRS) (fever, hypotension, hypoxia) and neurotoxicity (tremor, seizure, confusion, aphasia, facial palsy) are expected risk categories. Premedication often includes dexamethasone . Deeper CRS grading with tocilizumab lives with cellular therapy and the later emergency chapter; here the antibody-specific rule is stop or hold per protocol, do not speed the bag .

A 7-year-old whose parent "just disconnected the pump for a bath" has interrupted therapy. Assess the child for CRS and neuro change, secure a new closed system, and notify—do not run the next bag at twice the rate to make up the hour.

Intrathecal versus systemic immunotherapy

Systemic immunotherapy (checkpoint inhibitors, dinutuximab, blinatumomab) circulates, causes whole-body irAEs or CRS, and is given intravenously. Intrathecal immunotherapy delivers an agent into cerebrospinal fluid for sanctuary-site disease. Families sometimes lump IT antibodies and IT chemotherapy together as "immune shots in the back." The differences CPHON tests:

  • Feature Systemic immunotherapy Intrathecal immunotherapy
  • Route IV infusion (hours to multi-day bags) Lumbar puncture or Ommaya reservoir

Main toxicities irAEs, CRS, neuropathic pain, capillary leak Chemical arachnoiditis, headache, seizure, acute neuro change

Line and field rules Central-line security; never catch-up bolus a continuous bag Preservative-free, IT-labeled only; no vincristine on the field

Stop cue Hypotension, hypoxia, severe pain, new neuro change, anaphylaxis Acute encephalopathy, seizure, severe headache, wrong syringe

Family teaching Delayed irAEs can appear after discharge Post-LP positioning and leak precautions as ordered

IT product must be preservative-free and labeled for IT use. The same timeout used for IT methotrexate applies: two-nurse route check, no vinca on the tray. Do not assume an "immune" syringe is automatically safe for the spine.

Premeds and emergency stop parameters

Set up before the first drop: protocol premedications on time (antihistamine, acetaminophen, corticosteroid, hydration; opioids and gabapentinoids for dinutuximab); emergency medications at the bedside (epinephrine, extra antihistamine, corticosteroid, oxygen, suction, a working IV, and a dinutuximab pain-rescue plan); baseline weight, vitals, and neurologic exam for blinatumomab; and family teaching that pausing is safety.

Stop the infusion (or hold the continuous bag per protocol) for anaphylaxis (airway, wheeze, hypotension, widespread urticaria)—give epinephrine, do not finish the bag first; protocol-defined severe dinutuximab pain unresponsive to holds, rate cuts, and opioid rescue; capillary-leak crisis (refractory hypotension, hypoxia, or rapid weight gain with respiratory compromise); and new neurologic change on blinatumomab (seizure, aphasia, severe confusion). Mild isolated flushing or low-grade fever may be a rate decrease and notify . Restart only with an order.

The CPHON product is a nurse who can tell a family that checkpoints are not first-line for most toddlers, that steroids treat inflammatory irAEs, that dinutuximab pain is protocolized, that blinatumomab lives in a locked bag, and that IT immune products follow the same route timeout as IT methotrexate.

Loading diagram... Immunotherapy route, monitoring, and stop rules